651 related articles for article (PubMed ID: 19185785)
1. [Summary and perspectives. Rivaroxaban].
Albaladejo P
Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S28-31. PubMed ID: 19185785
[TBL] [Abstract][Full Text] [Related]
2. [Rivaroxaban (Xarelto): efficacy and safety].
Rosencher N; Arnaout L; Chabbouh T; Bellamy L
Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S22-7. PubMed ID: 19185784
[TBL] [Abstract][Full Text] [Related]
3. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Dumont B; Faille D; Ajzenberg N
Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Laux V; Perzborn E; Kubitza D; Misselwitz F
Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849
[TBL] [Abstract][Full Text] [Related]
5. [Rivaroxaban: mode of action].
Drouet L
Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S9-15. PubMed ID: 19185786
[TBL] [Abstract][Full Text] [Related]
6. [Prophylaxis of venous thromboembolism in orthopaedic surgery--trivial option, huge potential].
Saxer F; Dick W
Z Orthop Unfall; 2010 Jan; 148(1):26-30. PubMed ID: 20135590
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
[TBL] [Abstract][Full Text] [Related]
8. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.
Van Thiel D; Kalodiki E; Wahi R; Litinas E; Haque W; Rao G
Clin Appl Thromb Hemost; 2009; 15(4):389-94. PubMed ID: 19608550
[TBL] [Abstract][Full Text] [Related]
9. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban: new drug. After hip or knee replacement surgery: LMWH is safer.
Prescrire Int; 2009 Aug; 18(102):151-3. PubMed ID: 19743567
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Abrams PJ; Emerson CR
Pharmacotherapy; 2009 Feb; 29(2):167-81. PubMed ID: 19170587
[TBL] [Abstract][Full Text] [Related]
12. [Prophylaxis of thrombembolic diseases with rivaroxaban].
Gassanov N; Caglayan E; Erdmann E; Er F
Dtsch Med Wochenschr; 2010 Nov; 135(44):2189-92. PubMed ID: 20979005
[No Abstract] [Full Text] [Related]
13. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders.
Perzborn E; Kubitza D; Misselwitz F
Hamostaseologie; 2007 Sep; 27(4):282-9. PubMed ID: 17938768
[TBL] [Abstract][Full Text] [Related]
15. Oral rivaroxaban for symptomatic venous thromboembolism.
; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
[TBL] [Abstract][Full Text] [Related]
16. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban: a new oral factor Xa inhibitor.
Perzborn E; Roehrig S; Straub A; Kubitza D; Mueck W; Laux V
Arterioscler Thromb Vasc Biol; 2010 Mar; 30(3):376-81. PubMed ID: 20139357
[TBL] [Abstract][Full Text] [Related]
18. Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent.
Komotar RJ; Starke RM; Connolly ES
Neurosurgery; 2008 Oct; 63(4):N10-1. PubMed ID: 18981864
[No Abstract] [Full Text] [Related]
19. Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X.
Kakar P; Watson T; Lip GY
Curr Opin Investig Drugs; 2007 Mar; 8(3):256-65. PubMed ID: 17408122
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban, the first oral, direct factor Xa inhibitor.
Fassiadis N
Expert Opin Pharmacother; 2009 Dec; 10(18):2945-6. PubMed ID: 19925048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
